Advances in Frontline Gastric, GEJ, and Esophageal Adenocarcinoma From ESMO 2025 - Episode 5

Ongoing Research to Watch in Advanced Gastric/GEJ Cancer

December 1, 2025

Yelena Y. Janjigian, MD, Zev A. Wainberg, MD

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.

EP. 1: Current Standards and Unmet needs in Advanced Gastric/GEJ Cancer

EP. 2: EDGE-Gastric Trial: Breaking Down Data for Domvanalimab/Zimberelimab Plus Chemo in First-Line Gastric/GEJ/Esophageal Adenocarcinoma

EP. 3: Detailing the Ongoing Phase 3 STAR-221 Trial of Domvanalimab/Zimberelimab Plus FOLFOX in First-Line Gastric/GEJ/Esophageal Adenocarcinoma

EP. 4: Where Domvanalimab/Zimberelimab/Chemo Could Fit in the Advanced Gastric/GEJ/Esophageal Adenocarcinoma Paradigm

Now Viewing

EP. 5: Ongoing Research to Watch in Advanced Gastric/GEJ Cancer

EP. 6: Other Key Data in Gastric/GEJ Cancer Presented at ESMO 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, outline major ongoing research efforts aimed at improving outcomes for patients with advanced gastric and GEJ cancers. They emphasize the importance of continued evaluation of immunotherapy combinations, biomarker-directed approaches, and next-generation targeted therapies. Janjigian and Wainberg also highlight broader areas of investigation in gastrointestinal oncology that could shape future treatment paradigms.